[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (1,082)

Search Parameters:
Keywords = cardiovascular risk reduction

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
17 pages, 4534 KiB  
Article
Environmentally Relevant Sulfamethoxazole Induces Developmental Toxicity in Embryo-Larva of Marine Medaka (Oryzias melastigma)
by Jianxuan Huang, Lei Ye, Siyi Huang, Zuchun Chen, Jiahao Gao, Yangmei Li, Yusong Guo, Zhongduo Wang, Jian Liao, Zhongdian Dong and Ning Zhang
Fishes 2025, 10(3), 120; https://doi.org/10.3390/fishes10030120 (registering DOI) - 8 Mar 2025
Abstract
Sulfamethoxazole (SMX), a commonly used sulfonamide antibiotic, poses a threat to aquatic life due to its widespread presence in the environment. This study aims to investigate the specific effects of SMX on the development of marine medaka (Oryzias melastigma) embryos and [...] Read more.
Sulfamethoxazole (SMX), a commonly used sulfonamide antibiotic, poses a threat to aquatic life due to its widespread presence in the environment. This study aims to investigate the specific effects of SMX on the development of marine medaka (Oryzias melastigma) embryos and larvae. Marine medaka embryos were exposed to SMX at concentrations of 0 (solvent control group, SC group), 1 μg/L (low concentration group, L group), 60 μg/L (middle concentration group, M group), and 1000 μg/L (high concentration group, H group). The results indicated that SMX exposure significantly accelerated the heart rate of embryos (p < 0.0001) and shortened the hatching time while also causing anomalies such as reduced pigmentation, smaller eye size, spinal curvature, and yolk sac edema. SMX also led to a decrease in the total length of the larvae. The M group and the H group exhibited a significant increase (p < 0.05) in lipid accumulation in the visceral mass of the larvae. In the L group and the M group, there was a significant increase (p < 0.0001) in the swimming distance of the larvae. At the molecular level, SMX exposure affected the transcript levels of the genes involved in the cardiovascular system (ahrra, arnt2, atp2a1, and cacan1da), antioxidant and inflammatory systems (cat, cox-1, gpx, pparα, pparβ, and pparγ), nervous system (gap43, gfap, α-tubulin), intestinal barrier function (claudin-1), detoxification enzymes (ugt2c1-like), and lipid metabolism (rxraa) in the embryos to larval stage. The microbiome analysis showed that at the phylum level, exposure to SMX resulted in an increase in the abundance of Proteobacteria. Additionally, the abundance of Actinobacteriota significantly increased in the L group (p < 0.05). At the genus level, the abundance of Bifidobacterium significantly increased in the L group (p < 0.05), while the abundance of Vibrio significantly increased in the H group (p < 0.05). The alpha diversity analysis revealed a significant decrease in the Chao1 index in the L and H groups, indicating a reduction in microbial richness. The beta diversity analysis showed differences in the microbial communities of marine medaka larvae among different SMX exposure groups. This study elucidates the negative impacts of SMX on the development of marine medaka embryos and larvae and their microbial composition, providing a scientific basis for assessing the risks of SMX in marine ecosystems. Full article
(This article belongs to the Special Issue Toxicology of Anthropogenic Pollutants on Fish)
13 pages, 871 KiB  
Systematic Review
The Role of Chlorella and Spirulina as Adjuvants of Cardiovascular Risk Factor Control: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
by Mariana Pinto-Leite, Diana Martins, António Carlos Ferreira, Cláudia Silva, Fábio Trindade, Francisca Saraiva, Rui Vitorino, Raquel Barros, Pedro A. Lima, Adelino Leite-Moreira, João Pedro Ferreira, António S. Barros and Isabel M. Miranda
Nutrients 2025, 17(6), 943; https://doi.org/10.3390/nu17060943 (registering DOI) - 7 Mar 2025
Viewed by 171
Abstract
Background/Objectives: Chlorella and Spirulina supplementation may reduce the risk of cardiometabolic diseases by better controlling blood cholesterol, triglycerides, glucose, weight, and blood pressure (BP). However, the available studies are limited in size and have used different outcomes. Methods: To gain power [...] Read more.
Background/Objectives: Chlorella and Spirulina supplementation may reduce the risk of cardiometabolic diseases by better controlling blood cholesterol, triglycerides, glucose, weight, and blood pressure (BP). However, the available studies are limited in size and have used different outcomes. Methods: To gain power in assessing the impact of microalgae supplements on cardiovascular risk factors, we searched PubMed on 3 February 2023 for randomised controlled trials assessing the effects of Chlorella and Spirulina on modifiable cardiovascular risk factors. Results: We found 12 studies in Chlorella and 9 studies on Spirulina. Depending on the available outcomes, varying numbers of participants (Chlorella: 168 to 279; Spirulina: 101 to 299) were included. Our analysis showed that Chlorella supplementation had a neutral effect on BP and lipemia. On the other hand, Spirulina intake led to a significant reduction in diastolic BP (−0.42, 95% CI: −0.81 to −0.02, p = 0.04) but did not significantly affect lipemia indexes, despite a trend toward a reduction in total cholesterol (−0.17, 95% CI: −0.39 to 0.06, p = 0.15). This meta-analysis suggests Spirulina supplementation can be used as an adjuvant to control cardiometabolic risk factors, particularly for BP. However, the magnitude of this effect is small and of uncertain clinical significance. Conclusions: Further randomised trials are needed to better assess the potential of these supplements as adjuvants for the control of cardiovascular risk factors. Full article
(This article belongs to the Section Nutritional Epidemiology)
Show Figures

Figure 1

Figure 1
<p>Flow diagram of the study selection procedure.</p>
Full article ">Figure 2
<p>Effects of <span class="html-italic">Chlorella</span> and Spirulina treatment over the placebo on systolic (SPB) and diastolic (DPB) blood pressure, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TGs). The size of each dot represents the sample size. Vertical red lines denote the absence of an effect (standardised mean difference of 0). A leftward shift of the dots to the vertical lines, except for HDL-C, indicates a positive health effect.</p>
Full article ">
15 pages, 1235 KiB  
Review
Characterization and Management of Adverse Events of Low-Dose Oral Minoxidil Treatment for Alopecia: A Narrative Review
by Juan Jimenez-Cauhe, Kristen I. Lo Sicco, Jerry Shapiro, Angela Hermosa-Gelbard, Patricia Burgos-Blasco, Ana Melian-Olivera, Daniel Ortega-Quijano, Cristina Pindado-Ortega, Diego Buendia-Castaño, Daniel Asz-Sigall and Sergio Vaño-Galvan
J. Clin. Med. 2025, 14(6), 1805; https://doi.org/10.3390/jcm14061805 - 7 Mar 2025
Viewed by 151
Abstract
Low-dose oral minoxidil (LDOM) has emerged as a widely used off-label treatment for different types of alopecia, showing a favorable safety profile and effectiveness. Despite its growing use, it is essential to understand the possible associated adverse events (AEs) and their appropriate management [...] Read more.
Low-dose oral minoxidil (LDOM) has emerged as a widely used off-label treatment for different types of alopecia, showing a favorable safety profile and effectiveness. Despite its growing use, it is essential to understand the possible associated adverse events (AEs) and their appropriate management to optimize this therapy. The aim of this article was to comprehensively review the AEs of LDOM treatment, describing their frequency, risk factors, affected anatomical sites, and management strategies. A search in the PubMed and EMBASE databases was performed for studies published before 31 December 2024, reporting the treatment of any type of hair loss with oral minoxidil. The most frequent AE is hypertrichosis, occurring in approximately 15% of patients, with a higher incidence in women and patients with higher doses. Fluid retention affects 1.3–10% of patients, particularly women, and typically occurs within 1–3 months of treatment. Other cardiovascular AEs, such as tachycardia or dizziness, occur in fewer than 5% of cases and are usually mild and transient. Severe AEs, including pericardial effusion, are extremely rare and often linked to compounding errors comprising an excessive dose. Management strategies include dose reduction, pharmacological interventions like diuretics for edema, and lifestyle measures such as sodium restriction. In most cases, AEs resolve without the need for treatment discontinuation. The favorable safety profile of LDOM makes it a valuable therapeutic option for alopecia, though careful patient selection, dose titration, and monitoring are essential to minimize risks. Full article
(This article belongs to the Special Issue Autoimmune-Induced Alopecia and Emerging Therapies in Hair Loss)
Show Figures

Figure 1

Figure 1
<p>Chronological pattern of onset for the main adverse effects of LDOM. Adapted with permission from the work of Vaño-Galvan et al., 2021 [<a href="#B2-jcm-14-01805" class="html-bibr">2</a>]. Created with Biorender.com.</p>
Full article ">Figure 2
<p>Frequency of LDOM-induced hypertrichosis in facial and body areas. The colors represent a high (red), medium (yellow), or low (green) frequency of hypertrichosis. Adapted with permission from the work of Jimenez-Cauhe et al., 2021 [<a href="#B13-jcm-14-01805" class="html-bibr">13</a>]. Created with Biorender.com.</p>
Full article ">Figure 3
<p>Varying degrees of LDOM-induced hypertrichosis and their management. (<b>A</b>) Typical mild hypertrichosis on sideburns, not concerning for the patient. (<b>B</b>) Moderate hypertrichosis on sideburns, cheeks and neck, treated with bleaching. (<b>C</b>) Moderate hypertrichosis on arms, which required dose reduction due to patient concern regarding this AE.</p>
Full article ">
15 pages, 2454 KiB  
Article
Metformin Use and Clinical Outcomes in Autosomal Dominant Polycystic Kidney Disease: A Nationwide Cohort Study
by I-Ching Kuo, Ming-Yen Lin, Yu-Hsiang Tsao, Yi-Wen Chiu and Jia-Jung Lee
Biomedicines 2025, 13(3), 635; https://doi.org/10.3390/biomedicines13030635 - 5 Mar 2025
Viewed by 122
Abstract
Background/Objectives: Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic disorder marked by bilateral renal cysts and extrarenal manifestations, ultimately resulting in renal failure. Emerging research indicates that metformin might influence the intracellular mechanisms of ADPKD, though its clinical significance remains [...] Read more.
Background/Objectives: Autosomal dominant polycystic kidney disease (ADPKD) is a progressive genetic disorder marked by bilateral renal cysts and extrarenal manifestations, ultimately resulting in renal failure. Emerging research indicates that metformin might influence the intracellular mechanisms of ADPKD, though its clinical significance remains uncertain. Methods: We applied the Taiwan National Health Insurance Database (NHIRD) to investigate the clinical impact of metformin utilization in ADPKD patients in real-world practice. The metformin user group was defined by more than 90 days of usage. To mitigate selection bias, we established a non-user group with a 1:2 ratio, matching for age, sex, and comorbidities by a propensity score matching method. Results: A total of 10,222 ADPKD cases were identified in the NHIRD between 2009 and 2018. After matching, the metformin user group was composed of 778 cases with a mean age of 59.5 ± 13.9 years, and the non-user group of 1546 cases with a mean age of 59.3 ± 14.4 years. The time from the index date to the outcome of ESKD in ADPKD was 5.3 ± 2.2 years in the metformin user group and 5.3 ± 2.3 years in the metformin non-user group, respectively. The metformin user group exhibited a significant reduction in the risk of end-stage kidney disease (ESKD), as indicated in the fully adjusted model (0.75, 95% CI 0.58–0.97, p = 0.03). A decreased risk of major adverse cardiovascular events (MACEs) was noted in metformin users, with an adjusted hazard ratio (HR) of 0.78 (95% CI 0.65–0.95, p = 0.01). Sensitivity analysis showed similar results by excluding late-stage CKD (CKD stage 5 or erythropoietin-stimulating agents use). Conclusions: Metformin usage in real-world practice showed lower hazards of ESKD and MACEs in patients with ADPKD, except for those with advanced CKD. Full article
(This article belongs to the Section Endocrinology and Metabolism Research)
Show Figures

Figure 1

Figure 1
<p>Study design and patient selection flow chart.</p>
Full article ">Figure 2
<p>Kaplan–Meier analysis for (<b>a</b>) ESKD, (<b>b</b>) MACE, and (<b>c</b>) all-cause mortality among matched ADPKD cohort according to metformin use. Kaplan–Meier analysis for (<b>d</b>) ESKD (<b>e</b>) MACE (<b>f</b>) all-cause mortality among matched cohort with diagnoses of both ADPKD and DM, according to metformin use. Abbreviations: ADPKD: autosomal dominant polycystic kidney disease. DM: diabetes mellitus. ESKD: end-stage kidney disease. MACE: major adverse cardiovascular event.</p>
Full article ">Figure 2 Cont.
<p>Kaplan–Meier analysis for (<b>a</b>) ESKD, (<b>b</b>) MACE, and (<b>c</b>) all-cause mortality among matched ADPKD cohort according to metformin use. Kaplan–Meier analysis for (<b>d</b>) ESKD (<b>e</b>) MACE (<b>f</b>) all-cause mortality among matched cohort with diagnoses of both ADPKD and DM, according to metformin use. Abbreviations: ADPKD: autosomal dominant polycystic kidney disease. DM: diabetes mellitus. ESKD: end-stage kidney disease. MACE: major adverse cardiovascular event.</p>
Full article ">Figure 3
<p>Risk for ESKD and MACE by metformin use in subgroup analysis. Hazard ratios of (<b>a</b>) ESKD and (<b>b</b>) MACE among matched patients with ADPKD. (<b>c</b>) ESKD (<b>d</b>) MACE among matched patients with diagnoses of both ADPKD and DM. Abbreviations: ESKD: end-stage kidney disease. MACE: major adverse cardiovascular event. ADPKD: autosomal dominant polycystic kidney disease. CCI: Charlson comorbidity index. ACEI: angiotensin-converting enzyme inhibitor. ARB: angiotensin receptor blocker.</p>
Full article ">Figure 3 Cont.
<p>Risk for ESKD and MACE by metformin use in subgroup analysis. Hazard ratios of (<b>a</b>) ESKD and (<b>b</b>) MACE among matched patients with ADPKD. (<b>c</b>) ESKD (<b>d</b>) MACE among matched patients with diagnoses of both ADPKD and DM. Abbreviations: ESKD: end-stage kidney disease. MACE: major adverse cardiovascular event. ADPKD: autosomal dominant polycystic kidney disease. CCI: Charlson comorbidity index. ACEI: angiotensin-converting enzyme inhibitor. ARB: angiotensin receptor blocker.</p>
Full article ">
15 pages, 937 KiB  
Article
Tailored Exercise Intervention in Metabolic Syndrome: Cardiometabolic Improvements Beyond Weight Loss and Diet—A Prospective Observational Study
by Michele Braggio, Gianluigi Dorelli, Nicola Olivato, Vito Lamberti, Maria Teresa Valenti, Luca Dalle Carbonare and Mattia Cominacini
Nutrients 2025, 17(5), 872; https://doi.org/10.3390/nu17050872 - 28 Feb 2025
Viewed by 200
Abstract
Background: Metabolic syndrome (MS) is a cluster of cardiovascular and metabolic risk factors that increase the likelihood of both acute events and chronic conditions. While exercise has been shown to improve individual risk factors associated with MS; research on its effects on [...] Read more.
Background: Metabolic syndrome (MS) is a cluster of cardiovascular and metabolic risk factors that increase the likelihood of both acute events and chronic conditions. While exercise has been shown to improve individual risk factors associated with MS; research on its effects on MS as an integrated condition remains limited. This study aims to evaluate the effectiveness of a 6-month Adapted Personalized Motor Activity (AMPA) program for improving the health outcomes of individuals with MS. Methods: Seventy-one sedentary participants with MS (mean age: 63 ± 9.4 years, 46.5% female) completed a 6-month intervention, incorporating moderate-intensity aerobic and resistance training. Each participant received a personalized exercise plan prescribed by a sports medicine physician. The training was monitored via telemetry to ensure safety. No dietary recommendations were provided during the intervention. Baseline and post-intervention assessments included Cardiopulmonary Exercise Testing (CPET), anthropometric measurements, blood pressure, heart rate, lipid profile (total cholesterol, HDL, LDL, and triglycerides), fasting glucose, and HbA1c. Results: Significant improvements were observed in fasting glucose (−10.6%, p < 0.001), HbA1c (−3.88%, p < 0.001), HDL cholesterol (+20.8%, p < 0.001), LDL cholesterol (−25.1%, p < 0.001), and VO2max (+8.6%, p < 0.001). Systolic and diastolic blood pressure also decreased significantly, with reductions of −12% (p < 0.001) and −5.9% (p < 0.001), respectively. Reductions in weight and waist circumference were statistically significant but modest and clinically irrelevant, showing no correlation with improvements in cardio-metabolic parameters. Logistic regression and correlation matrix analyses were performed to identify key predictors of changes in individual risk factors. Conclusions: While personalized exercise alone may not fully control individual risk factors of metabolic syndrome, its overall effect is comparable to low-intensity pharmacological polytherapy with minimal adverse effects. These benefits appear to be independent of dietary habits, gender, and both baseline and post-intervention physical performance and anthropometric measures. Full article
(This article belongs to the Special Issue The Role of Physical Activity and Diet on Weight Management)
Show Figures

Figure 1

Figure 1
<p>Prevalence of individual metabolic syndrome risk factors in the study population. BMI, body mass index; HDL, high density lipoprotein; * A risk factor is considered present even when the patient is undergoing specific treatment for that condition.</p>
Full article ">Figure 2
<p>Percentage changes in the main variables observed after the AMPA intervention. HbA1c%, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; TG, triglycerides; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 s; VO<sub>2</sub>max, maximum oxygen consumption rate; Indexed VO<sub>2</sub>max, maximal oxygen consumption rate normalized to body weight; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure.</p>
Full article ">
26 pages, 9912 KiB  
Article
Therapeutic Potential of Cranberry Proanthocyanidins in Addressing the Pathophysiology of Metabolic Syndrome: A Scrutiny of Select Mechanisms of Action
by Francis Feldman, Mireille Koudoufio, Alain Théophile Sané, Valérie Marcil, Mathilde Foisy Sauvé, James Butcher, Natalie Patey, Catherine Martel, Schohraya Spahis, Haonan Duan, Daniel Figeys, Yves Desjardins, Alain Stintzi and Emile Levy
Antioxidants 2025, 14(3), 268; https://doi.org/10.3390/antiox14030268 - 26 Feb 2025
Viewed by 187
Abstract
Metabolic syndrome (MetS) constitutes a spectrum of interconnected conditions comprising obesity, dyslipidemia, hypertension, and insulin resistance (IR). While a singular, all-encompassing treatment for MetS remains elusive, an integrative approach involving tailored lifestyle modifications and emerging functional food therapies holds promise in preventing its [...] Read more.
Metabolic syndrome (MetS) constitutes a spectrum of interconnected conditions comprising obesity, dyslipidemia, hypertension, and insulin resistance (IR). While a singular, all-encompassing treatment for MetS remains elusive, an integrative approach involving tailored lifestyle modifications and emerging functional food therapies holds promise in preventing its multifaceted manifestations. Our main objective was to scrutinize the efficacy of cranberry proanthocyanidins (PAC, 200 mg/kg/day for 12 weeks) in mitigating MetS pathophysiology in male mice subjected to standard Chow or high-fat/high-fructose (HFHF) diets while unravelling intricate mechanisms. The administration of PAC, in conjunction with an HFHF diet, significantly averted obesity, evidenced by reductions in body weight, adiposity across various fat depots, and adipocyte hypertrophy. Similarly, PAC prevented HFHF-induced hyperglycemia and hyperinsulinemia while also lessening IR. Furthermore, PAC proved effective in alleviating key risk factors associated with cardiovascular diseases by diminishing plasma saturated fatty acids, as well as levels of triglycerides, cholesterol, and non-HDL-C levels. The rise in adiponectin and drop in circulating levels of inflammatory markers showcased PAC’s protective role against inflammation. To better clarify the mechanisms behind PAC actions, gut–liver axis parameters were examined, showing significant enhancements in gut microbiota composition, microbiota-derived metabolites, and marked reductions in intestinal and hepatic inflammation, liver steatosis, and key biomarkers associated with endoplasmic reticulum (ER) stress and lipid metabolism. This study enhances our understanding of the complex mechanisms underlying the development of MetS and provides valuable insights into how PAC may alleviate cardiometabolic dysfunction in HFHF mice. Full article
Show Figures

Figure 1

Figure 1
<p>Effect of PAC on caloric intake, body weight gain, and adiposity. Mice were fed either a standard Chow diet or a high-fat, high-fructose diet (HFHF) ± 200 mg/kg polyphenol proanthocyanidin-rich fraction (PAC) body weight/day by gavage for 12 weeks. Chow diet and HFHF-fed mice were gavaged with a water vehicle. (<b>A</b>) energy intake, (<b>B</b>) body weight gain, and (<b>C</b>) total weight gain over the 12-week period. (<b>D</b>) Total adipose tissue weight (as a total of collected fat pads) and (<b>E</b>) its tissue distribution. Results are presented as means ± SEM for <span class="html-italic">n</span> = 12 mice/group. * <span class="html-italic">p</span> &lt; 0.05, *** <span class="html-italic">p</span> &lt; 0.001 vs. Chow; <sup>#</sup> <span class="html-italic">p</span> &lt; 0.05, <sup>##</sup> <span class="html-italic">p</span> &lt; 0.01, <sup>###</sup> <span class="html-italic">p</span> &lt; 0.001 vs. HFHF mice. Representative images of adipocytes in mesenteric adipose tissue stained with HPS in mice fed (<b>F</b>) a Chow diet, (<b>G</b>) an HFHF diet, and (<b>H</b>) an HFHF + PAC diet are presented (magnification × 200, scale bar = 50 μm). (<b>I</b>) Adipocyte size distribution (%), (<b>J</b>) adipocyte area (μM<sup>2</sup>), and (<b>K</b>) adipocyte diameter (μM). Data are expressed as means ± SEM for <span class="html-italic">n</span> = 4 mice/group. *** <span class="html-italic">p</span> &lt; 0.001 vs. Chow; <sup>###</sup> <span class="html-italic">p</span> &lt; 0.001 vs. HFHF mice.</p>
Full article ">Figure 2
<p>Effect of PAC on insulin resistance, fasting lipid profile, lipoprotein composition, and inflammatory circulating biomarkers. At weeks 0, 6, and 10, (<b>A</b>) fasting glycemia and (<b>B</b>) fasting insulinemia was measured, enabling the calculation of the (<b>C</b>) Homeostatic model assessment of insulin resistance (HOMA-IR). At weeks 0, 6, 10, and 12, (<b>D</b>) fasting triglyceridemia and (<b>E</b>) fasting total cholesterolemia were measured. Results are presented as means ± SEM for <span class="html-italic">n</span> = 6–12 mice/group. At week 12, the lipid profile was further investigated to determine levels of (<b>F</b>) HDL-cholesterol and (<b>G</b>) non-HDL-cholesterol. Results are presented as means ± SEM for <span class="html-italic">n</span> = 4 pooled plasma/group. At week 12, plasma from <span class="html-italic">n</span> = 8 mice/group was collected and pooled for lipoprotein determination. Isolated fractions were first obtained via fast-protein liquid chromatography (FLPC) and then were analyzed to reveal content in (<b>H</b>) total cholesterol and (<b>I</b>) esterified cholesterol, as described in Materials and Methods. Circulating (<b>J</b>) adiponectin was measured at week 10. Circulating (<b>K</b>) interleukin-1-alpha (IL1A), (<b>L</b>) Monocyte Chemoattractant Protein-1 (MCP1), and (<b>M</b>) Tumor Necrosis Factor-alpha (TNFA) were obtained at week 12. Results are presented as means ± SEM for <span class="html-italic">n</span> = 6–8 mice/group. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001 vs. Chow; <sup>#</sup> <span class="html-italic">p</span> &lt; 0.05, <sup>##</sup> <span class="html-italic">p</span> &lt; 0.01, <sup>###</sup> <span class="html-italic">p</span> &lt; 0.001 vs. HFHF mice.</p>
Full article ">Figure 3
<p>Effect of PAC on hepatic lipid accumulation. Fixed, paraffin-embedded liver sections from Chow, high-fat, high fructose (HFHF) and HFHF + PAC-fed mice stained either with (<b>A</b>–<b>C</b>) Masson’s trichrome (magnification × 200, scale bar = 50 μm) or HPS ((<b>D</b>–<b>F</b>) magnification × 50, scale bar = 50 μm; (<b>G</b>–<b>I</b>) magnification × 630, scale bar = 50 μm); representative images for <span class="html-italic">n</span> = 4 mice/group are presented. (<b>J</b>) Liver weights were measured, and (<b>K</b>) triglycerides and (<b>L</b>) total cholesterol contents were quantified in liver tissues for <span class="html-italic">n</span> = 6–8 mice/group. Results are presented as means ± SEM for <span class="html-italic">n</span> = 8 mice/group. * <span class="html-italic">p</span> &lt; 0.05, *** <span class="html-italic">p</span> &lt; 0.001 vs. Chow; <sup>##</sup> <span class="html-italic">p</span> &lt; 0.01, <sup>###</sup> <span class="html-italic">p</span> &lt; 0.001 vs. HFHF mice.</p>
Full article ">Figure 4
<p>Effect of PAC of fatty acid composition across the gut–liver axis. Mice were fed either a standard Chow diet or a high-fat, high-fructose diet (HFHF) or HFHF + PAC for 12 weeks. Liver, jejunum, plasma, and mesenteric white adipose tissue (WAT) specimens were collected and submitted to high-performance liquid chromatography (HPLC) for fatty acid quantification of (<b>A</b>) total fatty acids, (<b>B</b>) saturated fatty acids, (<b>C</b>) arachidonic fatty acid and (<b>D</b>) ω-6/ω-3 calculated ratio. Data are expressed as means ± SEM relative to Chow for <span class="html-italic">n</span> = 6–8 mice/group. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001 vs. Chow; <sup>#</sup> <span class="html-italic">p</span> &lt; 0.05, <sup>##</sup> <span class="html-italic">p</span> &lt; 0.01 vs. HFHF mice.</p>
Full article ">Figure 5
<p>Effect of PAC on gut histology. Cross-sections of distal colon tissue were stained with HPS to evaluate the impact of PAC supplementation on intestinal morphology. Representative images of colon sections in mice fed (<b>A</b>) a Chow diet, (<b>B</b>) a high-fat, high-fructose (HFHF) diet, and (<b>C</b>) an HFHF + PAC diet are presented (magnification × 25, scale bar = 50 μm). Histological parameters assessed included (<b>D</b>) crypt depth, (<b>E</b>) muscle thickness, and (<b>F</b>) number of goblet cells per crypt; data are shown as the means ± SEM for <span class="html-italic">n</span> = 4 mice/group. (<b>G</b>) Colon weight was measured and expressed as the means ± SEM relative to Chow for <span class="html-italic">n</span> = 12 mice/group. mRNA was extracted from distal colon specimens, and gene expression of tight junction markers (<b>H</b>) claudin 1 (<span class="html-italic">Cldn1</span>), occludin (<span class="html-italic">Ocln</span>), and zonula occludens-1 (<span class="html-italic">ZO1</span>) were measured and expressed as the means ± SEM relative to Chow for <span class="html-italic">n</span> = 6–8 mice/group. * <span class="html-italic">p</span> &lt; 0.05, *** <span class="html-italic">p</span> &lt; 0.05 vs. Chow.</p>
Full article ">Figure 6
<p>Effect of PAC on inflammatory markers, reticulum stress markers, and lipid metabolism in the gut–liver axis. mRNA was extracted from liver, distal colon, and jejunum specimens in Chow-, high-fat, high-fructose (HFHF) and HFHF + PAC-fed mice. (<b>A</b>) Liver and (<b>B</b>) distal colon inflammation was evaluated through gene expression of cyclooxygenase-2 (<span class="html-italic">Cox2</span>), nuclear factor kappa B (<span class="html-italic">Nfkb</span>), inhibitor of kappa B (<span class="html-italic">Ikb</span>), the <span class="html-italic">Nfkb</span>/<span class="html-italic">Ikb</span> ratio, Tumor Necrosis Factor-alpha (<span class="html-italic">Tnfa</span>) and interleukin-6 (<span class="html-italic">Il6</span>). (<b>C</b>) Liver and (<b>D</b>) distal colon endoplasmic reticulum stress was evaluated through gene expression of Glucose-regulated protein 78 kDa (<span class="html-italic">Grp78</span>), Glucose-regulated protein 94 kDa (<span class="html-italic">Grp94</span>), Activating transcription factor 6 (<span class="html-italic">Atf6</span>), Inositol-requiring protein-1 (<span class="html-italic">Ire1</span>), Protein kinase RNA-like ER kinase (<span class="html-italic">Perk</span>) and X-box-binding protein (<span class="html-italic">Xbp1</span>). Liver and jejunum lipid metabolism was evaluated through gene expression of (<b>E</b>,<b>F</b>) Apolipoprotein B (<span class="html-italic">Apob</span>), (<b>E</b>,<b>F</b>) Microsomal triglyceride transfer protein (<span class="html-italic">Mttp</span>), (<b>E</b>,<b>F</b>) 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (<span class="html-italic">Hmgcr</span>), (<b>E</b>,<b>F</b>) LDL receptor (<span class="html-italic">Ldlr</span>), (<b>E</b>) Proprotein convertase subtilisin (<span class="html-italic">Pcsk9</span>), (<b>E</b>,<b>F</b>) cluster of differentiation antigen 36 (<span class="html-italic">Cd36</span>), (<b>E</b>,<b>F</b>) Niemann-Pick C1-like 1 (<span class="html-italic">Npc1l1</span>), (<b>E</b>) Scavenger receptor class B, member 1 (<span class="html-italic">Scarb1</span>), (<b>F</b>) Apolipoprotein A1 (<span class="html-italic">Apoa1</span>), and (<b>F</b>) ATP-binding cassette transporter 1 (<span class="html-italic">Abca1</span>). Data are expressed as the means ± SEM relative to Chow for <span class="html-italic">n</span> = 6–8 mice/group. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001 vs. Chow; <sup>#</sup> <span class="html-italic">p</span> &lt; 0.05, <sup>##</sup> <span class="html-italic">p</span> &lt; 0.01, <sup>###</sup> <span class="html-italic">p</span> &lt; 0.001 vs. HFHF mice.</p>
Full article ">Figure 7
<p>Effect of PAC on bile acid metabolism. (<b>A</b>) Bile acid pool size and composition were assessed in mice plasma, as described in the Materials and Methods section. Messenger RNA was extracted from liver and ileum specimens in Chow-, high-fat, high-fructose (HFHF), and HFHF + PAC-fed mice. Liver and ileum bile acid metabolism was evaluated through gene expression of (<b>B</b>,<b>C</b>) Retinoid X receptor (<span class="html-italic">Rxr</span>), (<b>B</b>,<b>C</b>) Small heterodimer partner (<span class="html-italic">Shp</span>), (<b>B</b>,<b>C</b>) Myeloid differentiation primary response 88 (<span class="html-italic">Myd88</span>), (<b>B</b>,<b>C</b>) Lipopolysaccharide-binding protein (<span class="html-italic">Lbp</span>), (<b>B</b>,<b>C</b>) Farnesoid X receptor (<span class="html-italic">Fxr</span>), (<b>B</b>) Cholesterol-7-alpha-hydroxylase (<span class="html-italic">Cyp7a1</span>), (<b>C</b>) Fibroblast growth factor 15 (<span class="html-italic">Fgf15</span>) and (<b>B</b>,<b>C</b>) <span class="html-italic">Cd14</span>. Data are expressed as the means ± SEM relative to Chow for <span class="html-italic">n</span> = 6–8 mice/group. * <span class="html-italic">p</span> &lt; 0.05 vs. Chow; <sup>#</sup> <span class="html-italic">p</span> &lt; 0.05, <sup>##</sup> <span class="html-italic">p</span> &lt; 0.01, <sup>###</sup> <span class="html-italic">p</span> &lt; 0.001 vs. HFHF mice.</p>
Full article ">Figure 8
<p>HFHF + PAC diet causes clear shifts to mouse microbiomes over time. Principal coordinate analysis using the unweighted Unifrac distance on all mouse microbiota (<b>A</b>) and each time point analyzed separately (<b>B</b>). Initial mouse microbiota all cluster together (Week 0; (<b>A</b>,<b>B</b>)) with HFHF diet, causing dramatic shifts in microbiota composition over time, while Chow-fed mice remain relatively consistent. Changes in species richness (Chao 1 index; (<b>C</b>)) and evenness (Shannon diversity; (<b>D</b>)) over time for each mouse group normalized to T0. HFHF mice have reduced microbial richness as compared to Chow. There was no significant change in species evenness throughout the experiment. Ellipses in B represent the 95% confidence intervals for each group. <span class="html-italic">n</span> = 8 mice/group. ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001 vs. Chow.</p>
Full article ">Figure 9
<p>PAC treatment results in the enrichment of specific bacterial species and increases in specific SCFAs when compared to baseline. (<b>A</b>) Selected amplicon sequence variants (ASVs) annotated and defined at the species level with differentially abundant changes over time. ASV relative abundance was log<sub>10</sub> transformed with a pseudocount added as required. Points represent each sample, with lines representing LOWESS fits and shaded regions denoting 95% confidence intervals. Bars along the <span class="html-italic">x</span>-axis highlight the time spans identified as showing different abundance patterns. The colour represents which group was enriched for each time period. (<b>B</b>) Levels of measured SCFAs in each feeding group at T0 and after 11 weeks of the dietary intervention (see <a href="#app1-antioxidants-14-00268" class="html-app">Supplementary Table S3</a> for overall variation between both endpoints (TΔ) in total SCFA and individual components). Boxplots show the interquartile range with the median represented as a line. <span class="html-italic">n</span> = 8 mice/group. * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01 vs. different timepoints.</p>
Full article ">
10 pages, 1224 KiB  
Article
Effect of Homoarginine on Coronary Artery Complexity and Atherosclerotic Burden in Patients with STEMI
by Gülsüm Bingöl, Ahmad Huraıbat, Elif Ayduk Gövdeli, Özgür Selim Ser, Serkan Ünlü, Murat Çelik, Leyla Bulut, Özge Özden, Emre Özmen and Kadriye Kılıçkesmez
J. Clin. Med. 2025, 14(5), 1501; https://doi.org/10.3390/jcm14051501 - 24 Feb 2025
Viewed by 201
Abstract
Objective: Homoarginine is a cationic amino acid derived from lysine. Evidence indicates that low-circulating homoarginine concentration is a risk factor for cardiovascular disease and all-cause mortality. A reduction in homoarginine concentrations has been observed in patients with ischemic heart disease, ischemic stroke, [...] Read more.
Objective: Homoarginine is a cationic amino acid derived from lysine. Evidence indicates that low-circulating homoarginine concentration is a risk factor for cardiovascular disease and all-cause mortality. A reduction in homoarginine concentrations has been observed in patients with ischemic heart disease, ischemic stroke, ischemic heart disease, and heart failure. The SYNTAX score (SS), an angiographic scoring system, defines the grade and complexity of coronary artery disease (CAD). The objective of this study was to evaluate the relationship between homoarginine level and the severity of CAD according to the SYNTAX score in patients with ST-segment elevation myocardial infarction (STEMI). Methods: A total of 67 subjects were enrolled into the study with the diagnosis of STEMI of those who underwent coronary angiography. STEMI patients were divided into two groups: low-medium SYNTAX score ≤ 14 (35 patients) and high SYNTAX score > 14 (32 patients). Results: Within the high SS group, serum homoarginine levels were markedly lower (2 ± 0.9 vs. 1.3 ± 0.7; p = 0.001). Homoarginine levels and SS showed a significant negative correlation in entire study cohort In multivariate regression analysis, serum homoarginine levels along with serum urea levels were significantly associated with having higher SS (OR 1.073 p = 0.049 and OR 0.346, p = 0.012, respectively). Conclusions: In conclusion, the diminished plasma homoarginine level emerges as an independent predictor of high atherosclerotic burden among STEMI patients. To the best of our knowledge, this is the first study to demonstrate the relationship between homoarginine and coronary artery complexity. Full article
(This article belongs to the Section Cardiovascular Medicine)
Show Figures

Figure 1

Figure 1
<p>Comparison of Homoarginine levels by Syntax score groups.</p>
Full article ">Figure 2
<p>Correlation graph of Homoarginine levels and Syntax score.</p>
Full article ">Figure 3
<p>ROC curve for Syntax score &gt; 14.</p>
Full article ">
18 pages, 1590 KiB  
Article
The Characterization of Atrial Fibrillation and Prognostic Value of a Modified 4S-AF Scheme: A Report from the REGUEIFA Community Health Area Registry (Galician Intercentric Registry of Atrial Fibrillation)
by Javier García Seara, Laila González Melchor, María Vázquez Caamaño, Emilio Fernández-Obanza Windcheid, Raquel Marzoa, Miriam Piñeiro Portela, Eva González Babarro, Pilar Cabanas Grandío, Olga Durán Bobín, Óscar Prada Delgado, Juliana Elices Teja, Evaristo Freire, Mario Gutiérrez Feijoo, Javier Muñiz, Francisco Gude, Eduardo Barge Caballero, Carlos González-Juanatey and on behalf of the REGUEIFA Investigators
J. Clin. Med. 2025, 14(5), 1483; https://doi.org/10.3390/jcm14051483 - 23 Feb 2025
Viewed by 224
Abstract
Background: The REGUEIFA registry aims to assess the contemporary treatment of patients with atrial fibrillation (AF) in the community health area of Galicia. Due to the prognostic relevance of anticoagulation status, we used it to differentiate patients by adding a category to the [...] Read more.
Background: The REGUEIFA registry aims to assess the contemporary treatment of patients with atrial fibrillation (AF) in the community health area of Galicia. Due to the prognostic relevance of anticoagulation status, we used it to differentiate patients by adding a category to the stroke domain of the 4S-AF score. Methods: A Cox proportional hazards analysis was used to identify the prognostic value of the modified 4S-AF score regarding mortality, cardiovascular mortality, and thromboembolic events. For bleeding events, we used a Poisson regression model to account for recurrent events. Results: When considering the stroke risk domain as a categorical variable, the risk stratification for all-cause mortality improved by more than 2 times (stroke risk: 2 vs. 1; hazard ratio (HR): 2.17; 95% confidence interval (CI): 1.03–4.55), p = 0.04). According to the Poisson regression model, the stroke risk domain was also an independent factor for hemorrhagic events (HR: 2.83; 95% CI 1.69–4.74, p < 0.001). For patients with permanent AF, the mortality rate was more than 2 times higher than that of patients with paroxysmal AF or their first episode of AF (HR: 2.53; 95% CI; 1.53–4.18); p < 0.001. Anticoagulation therapy was the only independent domain treatment associated with a reduction in all-cause mortality (HR: 0.41; 95% CI 0.19–0.89 p < 0.0023). Conclusions: The modification of the stroke risk score to reflect anticoagulation status may improve the characterization and stratification of overall mortality risk, as demonstrated in the contemporary AF cohort from the REGUEIFA study. The permanent form of AF was associated with a higher risk of overall mortality and cardiovascular mortality. Full article
(This article belongs to the Section Cardiovascular Medicine)
Show Figures

Figure 1

Figure 1
<p>Kaplan-Meier survival curves for all cause mortality (<b>A</b>) and cardiovascular mortality (<b>B</b>) adjusted with Bonferroni correction.</p>
Full article ">Figure 2
<p>Kaplan-Meier survival curves for thromboembolic events (<b>A</b>) and hemorrhagic events (<b>B</b>) adjusted with Bonferroni correction.</p>
Full article ">
20 pages, 1888 KiB  
Article
The Cholesterol Paradox in Long-Livers from a Sardinia Longevity Hot Spot (Blue Zone)
by Alessandra Errigo, Maria Pina Dore, Michele Portoghese and Giovanni Mario Pes
Nutrients 2025, 17(5), 765; https://doi.org/10.3390/nu17050765 - 21 Feb 2025
Viewed by 3938
Abstract
Background/Objectives: Hypercholesterolemia is commonly viewed as a risk factor for coronary heart disease; however, several studies have reported an inverse relationship between cholesterol levels and cardiovascular mortality, particularly in older adults. This “cholesterol paradox” challenges the conventional understanding of lipid metabolism. Despite [...] Read more.
Background/Objectives: Hypercholesterolemia is commonly viewed as a risk factor for coronary heart disease; however, several studies have reported an inverse relationship between cholesterol levels and cardiovascular mortality, particularly in older adults. This “cholesterol paradox” challenges the conventional understanding of lipid metabolism. Despite often being dismissed as a result of reverse causality, the precise causes of this paradox remain poorly understood. This study aimed to investigate the potential existence of the cholesterol paradox in a long-lived population from central Sardinia, Italy. Methods: We recruited 168 baseline nonagenarians (81 males, 87 females) from the longevity Blue Zone area in 2018 and followed them until December 2024. The lipid profile was determined for all participants according to current guidelines, and its impact on survival was analyzed with Kaplan–Meier curves and Cox proportional hazards regression models. Results: The median total cholesterol was 199.5 (range 89–314) mg/dL in males and 202.5 (range 89–324) mg/dL in females. Survival time was significantly longer in participants with LDL cholesterol (LDL-C) above 130 mg/dL compared to that in nonagenarians with LDL-C lower than 130 mg/dL (3.82 ± 1.88 years vs. 2.79 ± 1.56 years, p < 0.0001). Cox regression analysis revealed a significant reduction in the hazard ratio (HR) for mortality in participants with mild hypercholesterolemia (LDL-C ≥ 130 mg/dL) compared to that in those with normal cholesterol (OR 0.600, 95%CI 0.405–0.891). Conclusions: In the long-lived population examined, the cholesterol paradox was unlikely to be a reflection of reverse causality. Our results challenge the common view that longevity is invariably associated with low cholesterol levels. Furthermore, moderate hypercholesterolemia does not preclude the oldest adult from attaining advanced ages, contrary to common belief. Full article
(This article belongs to the Section Geriatric Nutrition)
Show Figures

Graphical abstract

Graphical abstract
Full article ">Figure 1
<p>Recruitment of participants.</p>
Full article ">Figure 2
<p>Baseline serum lipid parameters in 168 study participants.</p>
Full article ">Figure 3
<p>(<b>a</b>) High vs. low LDL-C in all participants; (<b>b</b>) high vs. low LDL-C among males; (<b>c</b>) high vs. low LDL-C among females; (<b>d</b>) high vs. low HDL-C in all participants; (<b>e</b>) high vs. low LDL-C among males; (<b>f</b>) high vs. low LDL-C among females. Pairwise comparison by log rank test.</p>
Full article ">
14 pages, 293 KiB  
Review
Cardiovascular Disease in HIV Patients: A Comprehensive Review of Current Knowledge and Clinical Implications
by Sorina Șoldea, Maria Iovănescu, Mihaela Berceanu, Oana Mirea, Victor Raicea, Maria Cristina Beznă, Alexandru Rocșoreanu and Ionuț Donoiu
Int. J. Mol. Sci. 2025, 26(5), 1837; https://doi.org/10.3390/ijms26051837 - 21 Feb 2025
Viewed by 284
Abstract
Cardiovascular involvement in patients with human immune deficiency (HIV) has gained significant attention as the improved life expectancy of individuals with HIV has changed the paradigm regarding the long-term impact of the virus on cardiovascular health. We reviewed current literature on the prevalence, [...] Read more.
Cardiovascular involvement in patients with human immune deficiency (HIV) has gained significant attention as the improved life expectancy of individuals with HIV has changed the paradigm regarding the long-term impact of the virus on cardiovascular health. We reviewed current literature on the prevalence, diagnosis, and unique characteristics of cardiovascular disease (CVD) in HIV patients, including those treated with protease inhibitors (PIs) and complementary therapies. The incidence of infectious, immunosuppressive, and nutritionally related pathologies in HIV patients has declined, largely due to advancements in highly active antiretroviral therapies (HAART) and supportive care. However, issues related to autoimmunity and chronic inflammation persist. Elevated levels of high-sensitivity C-reactive protein, along with activated cytokines and other pro-inflammatory molecules, are common in HIV patients and contribute significantly to the increased risk for endothelial dysfunction, coagulation disorders, and accelerated atherogenesis. The advent of HAART has significantly improved the prognosis for HIV patients, leading to prolonged life expectancy and a reduction in AIDS-related complications. However, this success has also resulted in a shift in the clinical presentation, with HIV patients showing more chronic and insidious cardiovascular manifestations. Full article
(This article belongs to the Special Issue Advanced Research on HIV Virus and Infection)
19 pages, 294 KiB  
Article
Therapeutic Education and Pharmacotherapeutic Follow-Up Protocol, a Useful Tool for the Improvement of Patients at Cardiovascular Risk in Community Pharmacies
by Pilar Buenavida Jurado, Mª José De la Matta Martín, Mª José Martín Calero and Rocío De la Puerta
J. Cardiovasc. Dev. Dis. 2025, 12(3), 80; https://doi.org/10.3390/jcdd12030080 - 20 Feb 2025
Viewed by 283
Abstract
The aim was to determine the influence of a complex intervention based on pharmacotherapeutic follow-up (PTF) and the application of therapeutic education (TE) protocols on the clinical and educational parameters of patients at cardiovascular risk (CVR) attending community pharmacies (CPs). A prospective, longitudinal, [...] Read more.
The aim was to determine the influence of a complex intervention based on pharmacotherapeutic follow-up (PTF) and the application of therapeutic education (TE) protocols on the clinical and educational parameters of patients at cardiovascular risk (CVR) attending community pharmacies (CPs). A prospective, longitudinal, randomized, controlled clinical trial was conducted over 6 months in patients from four Spanish CPs, divided into control (CG) and intervention (IG) groups. CG patients received usual pharmacy care and IG patients received a PTF- and TE-based intervention. The sample consisted of 85 elderly patients. After pharmaceutical follow-up of the IG patients, the following results were observed: significant reductions in cardiovascular risk (CVR) (p < 0.005), blood pressure (BP) (p < 0.05), and sedentary lifestyle (p < 0.001), as well as an improved knowledge of CVR and cardiovascular risk factors (CVRFs) (p < 0.001). Target values for BP were achieved in 27.2% of patients and for triglycerides in 12.4% of patients. The PTF of the patients showed that 29.2% did not have the expected response to some treatments, while 25% had untreated pathologies and 10% had adverse reactions. The TE protocols related to the patients’ educational needs, applied individually and in conjunction with the PTF, were able to improve their lifestyle habits, their knowledge of CVR, CVRFs, and pharmacotherapy, and their clinical parameters, and, thus, the level of development of their disease Full article
(This article belongs to the Special Issue Effects of Pharmaceutical Intervention on Cardiovascular Risk)
Show Figures

Graphical abstract

Graphical abstract
Full article ">
19 pages, 1238 KiB  
Review
Can Exercise-Mediated Adipose Browning Provide an Alternative Explanation for the Obesity Paradox?
by Jiani Zhao, Xuehan Li, Chunyu Liang and Yi Yan
Int. J. Mol. Sci. 2025, 26(5), 1790; https://doi.org/10.3390/ijms26051790 - 20 Feb 2025
Viewed by 229
Abstract
Overweight patients with cardiovascular disease (CVD) tend to survive longer than normal-weight patients, a phenomenon known as the “obesity paradox”. The phenotypic characteristics of adipose distribution in these patients (who survive longer) often reveal a larger proportion of subcutaneous white adipose tissue (scWAT), [...] Read more.
Overweight patients with cardiovascular disease (CVD) tend to survive longer than normal-weight patients, a phenomenon known as the “obesity paradox”. The phenotypic characteristics of adipose distribution in these patients (who survive longer) often reveal a larger proportion of subcutaneous white adipose tissue (scWAT), suggesting that the presence of scWAT is negatively associated with all-cause mortality and that scWAT appears to provide protective benefits in patients facing unhealthy states. Exercise-mediated browning is a crucial aspect of the benign remodeling process of adipose tissue (AT). Reduced accumulation, reduced inflammation, and associated adipokine secretion are directly related to the reduction in CVD mortality. This paper summarized the pathogenetic factors associated with AT accumulation in patients with CVD and analyzed the possible role and pathway of exercise-mediated adipose browning in reducing the risk of CVD and CVD-related mortality. It is suggested that exercise-mediated browning may provide a new perspective on the “obesity paradox”; that is, overweight CVD patients who have more scWAT may gain greater cardiovascular health benefits through exercise. Full article
(This article belongs to the Section Molecular Endocrinology and Metabolism)
Show Figures

Figure 1

Figure 1
<p>An important aspect of exercise in promoting cardiovascular health is that exercise promotes browning of WAT, and exercise promotes browning of scWAT more than vWAT. At the heart of the “obesity paradox” is that people with high BMI have higher scWAT and lower vWAT, resulting in a healthier phenotype. Therefore, exercise further promotes health by promoting the browning of scWAT in this population.</p>
Full article ">Figure 2
<p>Exercise not only improves cardiovascular health through WAT browning but also reduces fat mass and fat inflammation. The above benefits are more significant in scWAT. This explains the obesity paradox: people with more scWAT, even if they have a higher BMI, gain greater health benefits from exercise-stimulated WAT browning.</p>
Full article ">
15 pages, 1294 KiB  
Review
Smoking Cessation Strategies After Acute Coronary Syndrome
by Anum Nazir, Smrthi Shetty Ujjar, Moncef Oualid Seddiki, Mala Jheinga and Lampson Fan
J. Clin. Med. 2025, 14(4), 1388; https://doi.org/10.3390/jcm14041388 - 19 Feb 2025
Viewed by 323
Abstract
Smoking is one of the strongest modifiable risk factors for coronary artery disease. It is the cause of approximately 10–30% of deaths due to cardiovascular disease around the world. There is a 50% reduction in the risk of myocardial infarction by one year [...] Read more.
Smoking is one of the strongest modifiable risk factors for coronary artery disease. It is the cause of approximately 10–30% of deaths due to cardiovascular disease around the world. There is a 50% reduction in the risk of myocardial infarction by one year for people who successfully quit smoking. Considering the risk associated with smoking and the benefits of smoking cessation, it is important to identify and implement effective smoking cessation strategies. There are pharmacological as well as non-pharmacological interventions to assist in smoking cessation. Pharmacological therapies including nicotine replacement therapy; bupropion and varenicline have generally been studied more in patients with cardiovascular disease than the non-pharmacological interventions. Non-pharmacological strategies for smoking cessation include behavioural interventions such as counselling sessions and cognitive behavioural therapy. Studies and randomised controlled trials have demonstrated the safety of most of the pharmacological interventions. Nonetheless, the success rates are variable for the different pharmacological options. Data suggest that greater success can be achieved in smoking cessation with a combination of pharmacological and non-pharmacological treatment. However, more studies are needed to explore the best therapeutic options to improve the success of smoking cessation. Full article
(This article belongs to the Section Cardiology)
Show Figures

Figure 1

Figure 1
<p>Approaches to smoking cessation.</p>
Full article ">Figure 2
<p>Pharmacological therapies for smoking cessation.</p>
Full article ">
21 pages, 27128 KiB  
Article
Spatiotemporal Dynamics of PM2.5-Related Premature Deaths and the Role of Greening Improvement in Sustainable Urban Health Governance
by Peng Tang, Tianshu Liu, Xiandi Zheng and Jie Zheng
Atmosphere 2025, 16(2), 232; https://doi.org/10.3390/atmos16020232 - 18 Feb 2025
Viewed by 200
Abstract
Environmental particulate pollution is a major global environmental health risk factor, which is associated with numerous adverse health outcomes, negatively impacting public health in many countries, including China. Despite the implementation of strict air quality management policies in China and a significant reduction [...] Read more.
Environmental particulate pollution is a major global environmental health risk factor, which is associated with numerous adverse health outcomes, negatively impacting public health in many countries, including China. Despite the implementation of strict air quality management policies in China and a significant reduction in PM2.5 concentrations in recent years, the health burden caused by PM2.5 pollution has not decreased as expected. Therefore, a comprehensive analysis of the health burden caused by PM2.5 is necessary for more effective air quality management. This study makes an innovative contribution by integrating the Enhanced Vegetation Index (EVI), Normalized Difference Vegetation Index (NDVI), and Soil-Adjusted Vegetation Index (SAVI), providing a comprehensive framework to assess the health impacts of green space coverage, promoting healthy urban environments and sustainable development. Using Nanjing, China, as a case study, we constructed a health impact assessment system based on PM2.5 concentrations and quantitatively analyzed the spatiotemporal evolution of premature deaths caused by PM2.5 from 2000 to 2020. Using Multiscale Geographically Weighted Regression (MGWR), we explored the impact of greening improvement on premature deaths attributed to PM2.5 and proposed relevant sustainable governance strategies. The results showed that (1) premature deaths caused by PM2.5 in Nanjing could be divided into two stages: 2000–2015 and 2015–2020. During the second stage, deaths due to respiratory and cardiovascular diseases decreased by 3105 and 1714, respectively. (2) The spatial variation process was slow, with the overall evolution direction predominantly from the southeast to northwest, and the spatial distribution center gradually shifted southward. On a global scale, the Moran’s I index increased from 0.247251 and 0.240792 in 2000 to 0.472201 and 0.468193 in 2020. The hotspot analysis revealed that high–high correlations slowly gathered toward central Nanjing, while the proportion of cold spots increased. (3) The MGWR results indicated a significant negative correlation between changes in green spaces and PM2.5-related premature deaths, especially in densely vegetated areas. This study comprehensively considered the spatiotemporal changes in PM2.5-related premature deaths and examined the health benefits of green space improvement, providing valuable references for promoting healthy and sustainable urban environmental governance and air quality management. Full article
(This article belongs to the Section Air Quality)
Show Figures

Figure 1

Figure 1
<p>Study Area. (<b>A</b>) the map of China. (<b>B</b>) the administrative boundary of Jiangsu Province. (<b>C</b>) the administrative boundary and population distribution of Nanjing City.</p>
Full article ">Figure 2
<p>Spatial distribution of premature deaths from pM<sub>2.5</sub>-related diseases (2000–2020). (<b>A</b>) is the spatial distribution of premature deaths caused by respiratory diseases due to PM2.5; (<b>B</b>) is the spatial distribution of premature deaths caused by cardiovascular diseases due to PM2.5.</p>
Full article ">Figure 3
<p>Changes in number of premature deaths from PM<sub>2.5</sub>-related diseases.</p>
Full article ">Figure 4
<p>Standard deviation ellipses (<b>A1</b>): respiratory diseases; (<b>B1</b>): cardiovascular diseases. (<b>A`</b>,<b>B`</b>) the change of the center of the standard deviation ellipse.</p>
Full article ">Figure 5
<p>Cold and hot spot analysis (<b>A</b>–<b>E</b>): spatial distributions of cold and hot spots for PM<sub>2.5</sub>-induced premature deaths from respiratory diseases; (<b>F</b>–<b>J</b>): spatial distributions of cold and hot spots for PM<sub>2.5</sub>-induced premature deaths from cardiovascular diseases.The numbers in the image represent Z-scores. Positive values indicate high-value clusters, while negative values indicate low-value clusters.</p>
Full article ">Figure 6
<p>Change in proportions of cold and hot spot areas. R means the area proportion of respiratory system diseases; C means the area proportion of cardiovascular diseases.</p>
Full article ">Figure 7
<p>Multiscale Geographically Weighted Regression analysis of vegetation indices and HIA results. (<b>A</b>–<b>C</b>) the regression results of respiratory diseases caused by PM2.5 and vegetation index. (<b>D</b>–<b>F</b>) the regression results of cardiovascular diseases caused by PM2.5 and vegetation index.</p>
Full article ">
19 pages, 26334 KiB  
Article
Computational Fluid Dynamics-Driven Comparison of Endovascular Treatment Strategies for Penetrating Aortic Ulcer
by Katia Capellini, Emanuele Gasparotti, Vincenzo Castiglione, Cataldo Palmieri, Sergio Berti, Antonio Rizza and Simona Celi
J. Clin. Med. 2025, 14(4), 1290; https://doi.org/10.3390/jcm14041290 - 15 Feb 2025
Viewed by 285
Abstract
Background: Penetrating aortic ulcer (PAU) is an acute aortic syndrome characterized by a high rupture risk. There are several PAU-treatment procedures indicated for the management of this pathology associated with different effects on vessel morphology and hemodynamics. A deep evaluation of the different [...] Read more.
Background: Penetrating aortic ulcer (PAU) is an acute aortic syndrome characterized by a high rupture risk. There are several PAU-treatment procedures indicated for the management of this pathology associated with different effects on vessel morphology and hemodynamics. A deep evaluation of the different types of treatment may be helpful in decision making. Computational Fluid Dynamics (CFD) is a powerful tool for detailed inspection of cardiovascular diseases. The aim of this work was to implement a comparative analysis based on CFD evaluation of the effects of two type of PAU treatments. Methods: Thoracic endovascular aortic repair (TEVAR) with a left subclavian artery (LSA) branched aortic endograft (SBSG) and a hybrid approach including TEVAR and carotid-LSA bypass were considered. Aortic anatomical models were created from computed tomography (CT) images acquired before and after PAU treatment with SBSG for three patients. Starting from these models, a new aortic geometry corresponding to the outcome of the hybrid strategy was generated. Morphological analysis and CFD simulations were carried out for all aortic models to evaluate LSA outflow for the same predefined boundary conditions. Results: Reductions in LSA diameter were found between aortic models before and after the SBSG (18.2%, 20.8%, and 12.4% for CASE 1, CASE 2, and CASE 3, respectively). The flow rate at LSA changed between pre-configuration and aortic configuration after the PAU treatments: an averaged decrement of 1.08% and 7.5% was found for SBSG and the hybrid approach, respectively. The larger increase in pressure drop between the aortic arch and the LSA extremity was shown in the hybrid approach for all cases. Conclusions: CFD simulations suggest that SBSG preserves LSA perfusion more than a hybrid strategy and has less impact on thoracic aorta hemodynamics. Full article
Show Figures

Figure 1

Figure 1
<p>CT acquisitions pre-intervention (<b>a</b>,<b>c</b>,<b>e</b>) and CT acquisitions post-SBSG treatment (<b>b</b>,<b>d</b>,<b>f</b>) for the three cases. PAUs are indicated by red arrows.</p>
Full article ">Figure 2
<p>Assessment of bifurcation angle between aortic arch and LSA.</p>
Full article ">Figure 3
<p>Three-dimensional models of TA for PRE (<b>a</b>,<b>d</b>,<b>g</b>), SBSG (<b>b</b>,<b>e</b>,<b>h</b>) and HYBRID (<b>c</b>,<b>f</b>,<b>i</b>) configurations for CASE 1 (<b>a</b>–<b>c</b>), CASE 2 (<b>d</b>–<b>f</b>), and CASE 3 (<b>g</b>–<b>i</b>).</p>
Full article ">Figure 4
<p>Cross-sectional areas and maximum diameters of the extracted sections for the LSA for PRE (in green) and SBSG (in blue) configurations for CASE 1 (<b>a</b>,<b>b</b>), CASE 2 (<b>c</b>,<b>d</b>), and CASE 3 (<b>e</b>,<b>f</b>).</p>
Full article ">Figure 5
<p>Flow rate at LSA for the three configurations for CASE 1 (<b>a</b>), CASE 2 (<b>b</b>), and CASE 3 (<b>c</b>).</p>
Full article ">Figure 6
<p>Velocity streamlines at systolic peak for PRE (<b>a</b>,<b>d</b>,<b>g</b>), SBSG (<b>b</b>,<b>e</b>,<b>h</b>), and HYBRID (<b>c</b>,<b>f</b>,<b>i</b>) configurations for CASE 1 (<b>a</b>–<b>c</b>), CASE 2 (<b>d</b>–<b>f</b>), and CASE 3 (<b>g</b>–<b>i</b>).</p>
Full article ">Figure 7
<p>For each case, TAWSS distribution (<b>top</b>) and area exposed to low TAWSS values (&lt;0.4 Pa) (<b>bottom</b>).</p>
Full article ">Figure 8
<p>For each case, OSI distribution (<b>top</b>) and area exposed to high OSI values (&gt;0.25) (<b>bottom</b>).</p>
Full article ">Figure 9
<p>Comparison of ECAP distributions for each case for PRE, SBSG, and HYBRID configurations.</p>
Full article ">
Back to TopTop